ClinicalTrials.gg

Program

ABP-671

A development code. Also written as “ABP-671 plus allopurinol” and “ABP-671 Group”.

Its studies are mostly in Gout · Renal Insufficiency, Chronic · Hyperuricemia, led by 2 companies.

Furthest: phase 3, since Apr 5, 20238 company-led studies, 1 open or runningNext primary completion: Oct 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Atom Therapeutics41 open or runningphase 3since Apr 5, 2023Apr 5, 2023Oct 31, 2027phase 2 · NCT07323095
Jiangsu Atom Bioscience and Pharmaceutical40 open or runningphase 2since Nov 16, 2020Apr 4, 2019none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 4, 2019First study: phase 1 study in GoutNew to Jiangsu Atom Bioscience and PharmaceuticalJiangsu Atom Bioscience and Pharmaceutical · NCT03906006 · 32 enrolled · United States
  2. Aug 15, 2019Phase 1 study in HyperuricemiaJiangsu Atom Bioscience and Pharmaceutical · NCT04060173 · 27 enrolled · United States
  3. Mar 6, 2020Phase 1 study in GoutJiangsu Atom Bioscience and Pharmaceutical · NCT04303039 · 12 enrolled · United States
  4. Nov 16, 2020Phase 2 study in GoutJiangsu Atom Bioscience and Pharmaceutical · NCT04638543 · 60 enrolled · Australia
  5. Apr 5, 2023Atom Therapeutics's first study: phase 3 study in GoutNew to Atom TherapeuticsAtom Therapeutics · NCT05818085 · 300 enrolled · United States, Australia, Georgia and more
  6. Feb 12, 2024Phase 3 study in GoutAtom Therapeutics · NCT06276556 · 43 enrolled · United States, Australia, Georgia and more
  7. Dec 8, 2025Phase 2 study in Renal Insufficiency, ChronicAtom Therapeutics · NCT07323095 · 80 planned · Australia, China
  8. Dec 27, 2025Phase 1 study in GoutAtom Therapeutics · NCT07367971 · 22 enrolled · United States

Ahead

  1. Oct 31, 2027Primary completion: phase 2 study in Renal Insufficiency, ChronicAtom Therapeutics · NCT07323095

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07367971Gout · United States1CompletedAtom TherapeuticsAug 19, 202622
NCT07323095Renal Insufficiency, Chronic · Australia, China2RecruitingAtom TherapeuticsOct 31, 202780
NCT06276556Gout · United States, Australia, Georgia and more3TerminatedAtom TherapeuticsSep 5, 202443
NCT05818085Gout · United States, Australia, Georgia and more3CompletedAtom TherapeuticsJan 30, 2025300
NCT04638543Gout · Australia2CompletedJiangsu Atom Bioscience and PharmaceuticalOct 26, 202160
NCT04303039Gout · United States1CompletedJiangsu Atom Bioscience and PharmaceuticalJun 9, 202012
NCT04060173Hyperuricemia · United States1CompletedJiangsu Atom Bioscience and PharmaceuticalDec 29, 201927
NCT03906006Gout · United States1CompletedJiangsu Atom Bioscience and PharmaceuticalJun 20, 201932

How it is read

Names in the registry

  • “ABP-671”, 6 entries
  • “ABP-671 plus allopurinol”, 1 entry
  • “ABP-671 Group”, 1 entry

Codes read as this program: ABP671.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.